U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Aducanumab (marketed as Aduhelm) Information
  1. Postmarket Drug Safety Information for Patients and Providers

Aducanumab (marketed as Aduhelm) Information

Aduhelm is an amyloid beta-directed antibody indicated for the treatment of Alzheimer’s disease. It is approved under the accelerated approval pathway, which provides patients suffering from a serious disease earlier access to drugs when there is an expectation of clinical benefit despite some uncertainty about the clinical benefit of the drug. 

Accelerated approval is based upon the drug’s effect on what is called a “surrogate” endpoint—an endpoint that reflects the effect of the drug on an important aspect of the disease—where the drug’s effect on the surrogate endpoint is expected, but not established, to predict clinical benefit. In the case of Aduhelm, the surrogate endpoint is the reduction of amyloid beta plaque. 

This pathway requires the company to verify clinical benefit in a post-approval trial. If the sponsor cannot verify clinical benefit, the FDA may initiate proceedings to withdraw approval of the drug. 

Related Information

Labeling and Regulatory History from Drugs@FDA 

Back to Top